» Articles » PMID: 23747486

Association of Sustained High Plasma Trough Concentration of Voriconazole with the Incidence of Hepatotoxicity

Overview
Journal Clin Chim Acta
Specialty Biochemistry
Date 2013 Jun 11
PMID 23747486
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Therapeutic drug monitoring (TDM) of voriconazole is important to optimize efficacy and to minimize toxicity and intolerance. In this study, we evaluated the effect of sustained high plasma trough concentration of voriconazole on the incidence of hepatotoxicity in hospitalized Japanese patients.

Methods: Thirty-nine patients were divided into 3 groups according to trough concentrations in two consecutive TDMs: <4 μg/ml in the first TDM (group A, n=25), >4 μg/ml in the first and <4 μg/ml in the second TDM (group B, n=8), and >4 μg/ml in both first and second TDMs (group C, n=6).

Results: Incidences of hepatotoxicity in groups A, B and C were 16.0, 25.0 and 83.3%, and significant differences were observed between groups A and C and groups B and C. Multiple logistic regression analysis identified the classification into groups A, B and C as an independent variable of hepatotoxicity.

Conclusions: These results suggest that sustained high trough concentration of voriconazole may increase the risk of hepatotoxicity, and decreasing trough concentration to <4 μg/ml by dose adjustment after the initial TDM may reduce the incidence of hepatotoxicity in patients treated with voriconazole.

Citing Articles

Therapeutic Drug Monitoring of Antimicrobial Drugs in Children with Cancer: A New Tool for Personalized Medicine.

Masetti R, Bossu G, Muratore E, Leardini D, Gatti M, Di Sario R Paediatr Drugs. 2024; 27(1):41-56.

PMID: 39503988 DOI: 10.1007/s40272-024-00663-5.


Voriconazole in the treatment of invasive aspergillosis of orbit.

Shilpy N, Pushker N, Meel R, Agrawal S, Bajaj M, Sharma S Med J Armed Forces India. 2024; 80(5):541-546.

PMID: 39309577 PMC: 11411301. DOI: 10.1016/j.mjafi.2022.08.002.


The Role of Plasma Trough Concentration of Voriconazole and Voriconazole N-Oxide in Its Hepatotoxicity in Adult Patients.

Cheng L, You X, Wang X, Yu M, Jia C Drug Des Devel Ther. 2024; 18:3617-3628.

PMID: 39156484 PMC: 11330242. DOI: 10.2147/DDDT.S475706.


The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals.

Li G, Li Q, Zhang C, Yu Q, Li Q, Zhou X Front Genet. 2023; 14:1242711.

PMID: 37693307 PMC: 10484623. DOI: 10.3389/fgene.2023.1242711.


Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis.

Jiang Z, Wei Y, Huang W, Li B, Zhou S, Liao L Front Pharmacol. 2022; 13:982981.

PMID: 36225581 PMC: 9549404. DOI: 10.3389/fphar.2022.982981.